Vertex Pharmaceuticals
VRTX
505.64
+3.33
+0.66%
Vertex Pharmaceuticals
US · VRTX
#155 by market cap
Listed 1970
505.64
+3.33
+0.66%
Live - 5344 symbols - heartbeat 24s ago
· 2026-10-08 08:19
Pre-market
506.67
+0.20%
After-hours
505.80
+0.03%
Overnight
505.01
-0.12%
- Market cap
- 128.16B
- P/E (TTM)i
- 29.45
- P/Bi
- 6.33
- EPSi
- 15.32
- Div yieldi
- 0.00%
- 52W posi
- 65%
Reader sentiment
Are you bullish or bearish on VRTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 13.16, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +8.90% YoY
Margins
- Gross margin
- 86.24%
- Operating margin
- 37.95%
- Net margin
- 32.94%
Key ratios & quality
- PEG ratioi
- 4.93
- Altman Z-Scorei
- 13.16
PEG uses trailing P/E against the 3-year net income growth rate (5.97%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.05B | 4.16B | 6.21B | 7.57B | 8.93B | 9.87B | 11.02B | 12.00B |
| Gross profit | 2.64B | 3.62B | 5.47B | 6.67B | 7.85B | 8.61B | 9.49B | 10.35B |
| Selling & admin expenses | 557.62M | 658.50M | 770.50M | 840.10M | 944.70M | 1.14B | 1.46B | 1.75B |
| Research & development | 1.42B | 1.75B | 1.83B | 3.05B | 2.66B | 3.69B | 8.26B | 4.04B |
| Operating profit | 663.97M | 1.20B | 2.87B | 2.78B | 4.25B | 3.78B | -233.40M | 4.55B |
| Pretax profit | 600.24M | 1.39B | 3.12B | 2.73B | 4.23B | 4.38B | 248.50M | 4.64B |
| Tax | -1.49B | 218.10M | 405.20M | 388.30M | 910.40M | 760.20M | 784.10M | 690.00M |
| Net profit | 2.09B | 1.18B | 2.71B | 2.34B | 3.32B | 3.62B | -535.60M | 3.95B |
| Basic EPS | 8 | 5 | 10 | 9 | 13 | 14 | -2 | 15 |
| Diluted EPS | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.77B | 2.96B | 3.08B | 3.19B | 2.99B | 3.33B |
| Gross profit | 2.41B | 2.56B | 2.66B | 2.72B | 2.59B | 2.84B |
| Selling & admin expenses | 396.40M | 424.60M | 445.10M | 487.00M | 493.70M | 582.20M |
| Research & development | 979.70M | 978.40M | 977.70M | 1.11B | 961.60M | 993.80M |
| Operating profit | 1.03B | 1.15B | 1.24B | 1.13B | 1.14B | 1.27B |
| Pretax profit | 730.40M | 1.28B | 1.30B | 1.33B | 1.25B | 1.39B |
| Tax | 84.10M | 250.10M | 215.90M | 139.90M | 221.50M | 292.00M |
| Net profit | 646.30M | 1.03B | 1.08B | 1.19B | 1.03B | 1.10B |
| Basic EPS | 3 | 4 | 4 | 5 | 4 | 4 |
| Diluted EPS | 2.49 | 3.99 | 4.20 | 4.65 | 4.02 | 4.31 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 3.84B | 4.82B | 8.13B | 9.56B | 13.23B | 14.14B | 9.60B | 11.20B |
| Cash & ST investments | 3.17B | 3.81B | 6.66B | 7.52B | 10.78B | 11.22B | 6.12B | 6.61B |
| Inventory | 124.36M | 167.50M | 280.80M | 353.10M | 460.60M | 738.80M | 1.21B | 1.69B |
| Total assets | 6.25B | 8.32B | 11.75B | 13.43B | 18.15B | 22.73B | 22.53B | 25.64B |
| Total current liabilities | 1.12B | 1.33B | 1.88B | 2.14B | 2.74B | 3.55B | 3.56B | 3.86B |
| Short-term debt | 5.27M | 38.79M | 42.40M | 80.20M | 89.40M | 83.70M | 87.10M | 77.30M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,810,695,000.00 | 2,233,221,000.00 | 3,065,000,000.00 | 3,332,500,000.00 | 4,238,200,000.00 | 5,149,800,000.00 | 6,123,600,000.00 | 6,977,200,000.00 |
| Total equity | 4.44B | 6.09B | 8.69B | 10.10B | 13.91B | 17.58B | 16.41B | 18.67B |
| Retained earnings | -2.99B | -1.85B | 858.70M | 3.20B | 6.52B | 10.14B | 9.61B | 13.56B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 10.01B | 10.43B | 10.57B | 11.20B | 11.73B | 12.54B |
| Cash & ST investments | 6.20B | 6.38B | 6.29B | 6.61B | 7.25B | 7.85B |
| Inventory | 1.36B | 1.50B | 1.63B | 1.69B | 1.77B | 1.77B |
| Total assets | 22.88B | 24.04B | 24.86B | 25.64B | 26.48B | 27.42B |
| Total current liabilities | 3.78B | 4.14B | 4.48B | 3.86B | 3.88B | 3.94B |
| Short-term debt | -- | -- | -- | 77.30M | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 6,384,200,000.00 | 6,861,300,000.00 | 7,543,500,000.00 | 6,977,200,000.00 | 7,122,500,000.00 | 7,175,400,000.00 |
| Total equity | 16.50B | 17.18B | 17.32B | 18.67B | 19.36B | 20.25B |
| Retained earnings | 10.25B | 11.29B | 12.37B | 13.56B | 14.59B | 15.69B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.27B | 1.57B | 3.25B | 2.64B | 4.13B | 3.54B | -492.60M | 3.63B |
| Depreciation & amortization | 72.42M | 106.90M | 109.50M | 125.60M | 148.30M | 181.30M | 207.20M | 209.80M |
| Free cash flow | 1.17B | 1.49B | 2.99B | 2.41B | 3.93B | 3.28B | -978.00M | 3.19B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -350.04M | -192.00M | -739.40M | -1.56B | -172.00M | -653.70M | -1.58B | -2.39B |
| Ending cash balance | 2.66B | 3.12B | 5.99B | 6.80B | 10.51B | 10.37B | 4.57B | 5.09B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 818.90M | 1.07B | 1.24B | 498.00M | 1.43B | 1.13B |
| Depreciation & amortization | 48.40M | 51.70M | 54.00M | 55.70M | 55.90M | 56.50M |
| Free cash flow | 778.20M | 927.40M | 1.14B | 348.60M | 1.29B | 1.01B |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -696.60M | -397.70M | -1.16B | -130.90M | -565.40M | -473.80M |
| Ending cash balance | 4.69B | 4.98B | 4.95B | 5.09B | 5.50B | 6.15B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 64.87 | 22.37 | 36.71 | 24.93 | 27.67 | 22.99 | -3.15 | 22.54 |
| ROA %i | 42.82 | 16.16 | 27.02 | 18.60 | 21.04 | 17.71 | -2.37 | 16.41 |
| ROIC %i | 55.38 | 19.93 | 33.54 | 23.15 | 25.16 | 18.96 | -5.38 | 18.26 |
| 5-year avg ROE %i | -9.05 | 7.57 | 25.96 | 33.08 | 35.31 | 26.93 | 21.83 | 19.00 |
| EBIT margin %i | 20.82 | 34.91 | 51.16 | 36.86 | 48.01 | 44.83 | 2.53 | 38.80 |
| FCF / sales %i | 38.55 | 35.89 | 48.24 | 31.80 | 43.95 | 33.22 | -- | 26.61 |
| Current ratioi | 3.43 | 3.61 | 4.33 | 4.46 | 4.83 | 3.99 | 2.69 | 2.90 |
| Quick ratioi | 3.19 | 3.33 | 4.02 | 4.04 | 4.46 | 3.60 | 2.17 | 2.24 |
| Debt / assetsi | 9.40 | 7.95 | 7.93 | 7.20 | 4.96 | 3.56 | 7.74 | 7.92 |
| LT debt / equityi | 13.11 | 10.24 | 10.24 | 8.78 | 5.82 | 4.12 | 10.10 | 10.46 |
| Interest coveragei | 18.59 | 24.84 | 54.60 | 45.40 | 78.23 | 100.32 | 9.12 | 350.11 |
| Revenue CAGR (3Y) %i | 43.45 | 34.73 | 35.60 | 35.46 | 28.97 | 16.73 | 13.31 | 10.35 |
| Net income CAGR (3Y) %i | -- | -- | 117.52 | 3.76 | 41.33 | 10.10 | -- | 5.97 |
| FCF CAGR (3Y) %i | -- | 102.64 | 72.27 | 27.03 | 37.99 | 3.08 | -- | -6.64 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -5.64 | 22.77 | 22.31 | 22.54 | 24.20 | 23.54 |
| ROA %i | -4.23 | 16.47 | 15.60 | 16.41 | 17.58 | 17.12 |
| ROIC %i | -7.46 | 18.79 | 17.95 | 18.26 | 19.89 | 19.53 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -2.50 | 38.45 | 38.06 | 38.80 | 38.99 | 38.76 |
| FCF / sales %i | -- | 30.65 | 28.47 | 26.61 | 30.37 | 30.16 |
| Current ratioi | 2.65 | 2.52 | 2.36 | 2.90 | 3.02 | 3.19 |
| Quick ratioi | 2.12 | 2.00 | 1.84 | 2.24 | 2.38 | 2.54 |
| Debt / assetsi | 7.21 | 6.35 | 7.38 | 7.92 | 7.50 | 7.21 |
| LT debt / equityi | 10.00 | 8.89 | 10.59 | 10.46 | 10.26 | 9.77 |
| Interest coveragei | -11.94 | 258.29 | 348.55 | 350.11 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- TRIKAFTA/KAFTRIO is the largest reported line at 74.90% of revenue, across 5 reported segments.
- The next-largest line, ALYFTREK, is a distant second at 17.21% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
TRIKAFTA/KAFTRIO74.90%
ALYFTREK17.21%
Other cystic fibrosis (CF) products4.11%
CASGEVY2.29%
JOURNAVX1.49%
Quote time 2026-10-08 08:19:31 · For reference only, not investment advice and not tailored to your situation.